Brief: Axovant Gene Therapies Reports Q4 Loss Per Share Of $0.54

Sio Gene Therapies

10/06/2020 11:10

June 10 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT ANNOUNCES YEAR-END FINANCIAL RESULTS AND EXPECTED
KEY
CLINICAL MILESTONES IN Q4 2020
    * Q4 LOSS PER SHARE $0.54
    * Q4 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES
DATA
    * CASH POSITION OF $80.8 MILLION AS OF MARCH 31, 2020 AND
EXPECTED
RUNWAY INTO SECOND CALENDAR QUARTER OF 2021
    * DATA FROM COHORT 2 OF SUNRISE-PD PHASE 2 STUDY OF
AXO-LENTI-PD
IN PARKINSON'S DISEASE EXPECTED IN Q4

Source text for Eikon:  ID:nGNXcgc4Cm 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))